Bio-Rad Laboratories, Inc. BIO.B
365.08
0.00
0.00%
as of 24 Sep
- Market cap
- $10.3B
- P/E
- 43.8×
Follow BIO.B
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(9.50%) | 10.84% | 2.50% | 3.11% | |
| (6.66%) | 7.62% | 1.75% | 2.17% | ||
ROIC |
2.15% | 0.41% | 0.55% | 0.49% | |
Return on Tangible Assets |
(23.63%) | 25.94% | 6.61% | 8.63% | |
Average Days of Receivables |
66.32 | 65.08 | 60.07 | 62.28 | |
Free Cash Flow per Share |
12.51 | 13.74 | 13.26 | 13.20 | |
Free Cash Flow |
336.90 | 374.70 | 357.40 | 353.10 | |
Capital Expenditures |
(154.60) | (157.50) | (153.00) | (139.50) | |
Piotroski F-Score |
4.00 | 5.00 | 6.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
5.25% | 5.22% | 5.31% | 4.93% | |
Accounts Receivable Turnover |
5.52 | 5.66 | 6.09 | 5.68 | |
Accounts Payable Turnover |
9.73 | 9.89 | 9.20 | 8.81 | |
Inventory Turnover |
1.54 | 1.66 | 1.60 | 1.58 | |
Average Days of Payables |
38.51 | 37.87 | 38.97 | 42.05 | |
Days of Inventory on Hand |
234.16 | 217.45 | 225.60 | 228.76 | |
Tax Rate |
(0.20) | (0.24) | (0.24) | (0.37) | |
Research and Development Expense of Revenue |
11.59% | 0.00% | 0.00% | 10.29% | |
Selling, General and Administrative Expense of Revenue |
32.35% | 32.68% | 32.74% | 32.91% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.73) | 0.70 | 3.02 | 2.21 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
94.99 | 94.75 | 96.07 | 96.81 | |
Operating CF per Share |
18.26 | 19.52 | 18.93 | 18.42 | |
Capex per Share |
(5.74) | (5.78) | (5.68) | (5.22) | |
Capex to Sales |
0.06 | 0.06 | 0.06 | 0.05 | |
Net Profit Margin |
(26.43%) | 29.42% | 6.52% | 8.59% |
Columns are period end dates